12,372 trials
Von Willebrand Disease
Primary: Total Annualised Bleeding Rate (TABR) During Prophylactic Treatment With Wilate. — 4.6; 3.7 Annualized number of bleeding episodes
Macrophage Activation Syndrome · Secondary Hemophagocytic Lymphohistiocytosis · Still Disease
Primary: Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab — 11; 4 Participants
Chronic Sinusitis · Chronic Rhinosinusitis (Diagnosis)
Primary: Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps — -2.73; -1.61 Change from Baseline in…
Fabry Disease
Primary: Change From Baseline in Lyso Gb3 Serum Levels — 4.99; 5.12; 4.95; 5.14 Nmol/L
Glabellar Lines
Primary: Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar…
Knee Osteoarthritis
Primary: Change From Baseline in OA Pain in the Target Knee (Pain NRS) — -2.24; -2.49 units on a scale — p=0.185
Vasomotor Symptoms Associated With Menopause · Hot Flashes
Primary: Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD]). — 13.38; 14.26; -7.48; -4.37 Hot Flashes per day…
Infertility, Female
Primary: Number of Oocytes Retrieved — 12.7; 11.8 Oocytes retrieved
Vasomotor Symptoms Associated With Menopause · Hot Flashes
Primary: Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD) — 14.66; 16.16; -8.58; -6.07 Hot Flashes per day — p=< 0.0001
Chemotherapy-induced Thrombocytopenia
Primary: Percentage of Participants Who Had Thrombocytopenia-induced Dose Modification — 84.4; 35.7 percentage of participants — p=< 0.001
Urinary Tract Infections
Primary: Percentage of Participants Achieving Clinical Symptom Improvement at 24 Hours (±4 Hours) — 54.4 Percentage of participants
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Primary: Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication — 1.3; 1.3; 1.5; 0.8 years
Postmenopausal Osteoporosis
Primary: To Evaluate the Efficacy of ENZ215 When Compared to Prolia in Patients With Postmenopausal Osteoporosis, in Terms of Change in Bone Mineral Density (BMD) at Lumbar…
Dry Eye Disease
Primary: Mean Change From Baseline in Tear Meniscus Height (TMH) at Minute 3 - Stage 1 — 519.65 micrometers — p=<0.0001
Infections, Meningococcal
Primary: Number of Participants Reporting Any Solicited Administration Site Events After the First Vaccination Administered at Day 1 — 156; 100; 39; 25 Participants